The company earned $675 million, or 59 cents per share, up from $599 million, or 51 cents per share, during the same period last year. Revenue rose almost 8 percent to $3.13 billion.

Not counting special items, Medtronic said it earned 62 cents per share. That matched the expectation of analysts.

Non-U.S. revenue of $1.18 billion was up 16 percent. For the quarter, 38 percent of Medtronic's revenue came from outside the United States.

Medtronic said the Food and Drug Administration would review its Endeavor drug-coated stent in October. On Tuesday, Chief Financial Officer Gary Ellis said it is reasonable to think Medtronic might see $30 million a month in U.S. sales for Endeavor.

Medtronic shares closed down 16 cents at $52.86. After its results were released, shares dropped $1.29, or 2.4 percent, to $51.57 in trading after the market closed.